EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Modeling antisense oligonucleotide therapy in MECP2 duplication syndrome human iPSC-derived neurons reveals gene expression programs responsive to MeCP2 levels

Sameer S Bajikar, Yehezkel Sztainberg, Alexander J Trostle, Harini P Tirumala, Ying-Wooi Wan, Caroline L Harrop, Jesse D Bengtsson, Claudia M B Carvalho iD, Davut Pehlivan, Bernhard Suter, Jeffrey L Neul, Zhandong Liu und 3 weitere

Human Molecular Genetics · 08.11.2024 · 33 (22) · 1986-2001

DOI: 10.1093/hmg/ddae135 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Molecular Genetics, online erschienen am 15.09.2024. Verfasst von Sameer S Bajikar und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, United States. Hauptthemen laut MEDLINE: Methyl-CpG-Binding Protein 2, Induced Pluripotent Stem Cells, Neurons, X-Linked Intellectual Disability. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, Howard Hughes Medical Institute, NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Genomic copy-number variations (CNVs) that can cause neurodevelopmental disorders often encompass many genes, which complicates our understanding of how individual genes within a CNV contribute to pathology. MECP2 duplication syndrome (MDS or MRXSL in OMIM; OMIM#300260) is one such CNV disorder caused by duplications spanning methyl CpG-binding protein 2 (MECP2) and other genes on Xq28. Using an antisense oligonucleotide (ASO) to normalize MECP2 dosage is sufficient to rescue abnormal neurological phenotypes in mouse models overexpressing MECP2 alone, implicating the importance of increased MECP2 dosage within CNVs of Xq28. However, because MDS CNVs span MECP2 and additional genes, we generated human neurons from multiple MDS patient-derived induced pluripotent cells (iPSCs) to evaluate the benefit of using an ASO against MECP2 in a MDS human neuronal context. Importantly, we identified a signature of genes that is partially and qualitatively modulated upon ASO treatment, pinpointed genes sensitive to MeCP2 function, and altered in a model of Rett syndrome, a neurological disorder caused by loss of MeCP2 function. Furthermore, the signature contained genes that are aberrantly altered in unaffected control human neurons upon MeCP2 depletion, revealing gene expression programs qualitatively sensitive to MeCP2 levels in human neurons. Lastly, ASO treatment led to a partial rescue of abnormal neuronal morphology in MDS neurons. All together, these data demonstrate that ASOs targeting MECP2 benefit human MDS neurons. Moreover, our study establishes a paradigm by which to evaluate the contribution of individual genes within a CNV to pathogenesis and to assess their potential as a therapeutic target.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Methyl-CpG-Binding Protein 2Induced Pluripotent Stem CellsNeuronsX-Linked Intellectual DisabilityOligonucleotides, AntisenseHumansMiceAnimalsRett SyndromeDNA Copy Number VariationsGene Expression Regulation

Stichwörter der Autor:innen

copy-number gaingenetic syndromesgenomic disorderiPSC derived neuronstranscriptomics

Substanzen

Methyl-CpG-Binding Protein 2MECP2 protein, humanOligonucleotides, Antisense

Autor:innen und Institutionen

  • Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, United States.
  • Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, 1250 Moursund Street, Houston, TX 77030, United States.
  • Department of Cell Biology, University of Virginia, 1340 Jefferson Park Avenue, Charlottesville, VA 22903, United States.
  • Department of Biomedical Engineering, University of Virginia, 415 Lane Road, Charlottesville, VA 22903, United States.
  • Department of Pediatrics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, United States.
  • Pacific Northwest Research Institute, 720 Broadway, Seattle, WA 98122, United States.

ORCID-Profile: Claudia M B Carvalho, Huda Y Zoghbi

Förderung

  • NINDS NIH HHS
  • Howard Hughes Medical Institute
  • NICHD NIH HHS
  • Eunice Kennedy Shriver National Institute of Child Health and Development
  • National Institute of National Institute of General Medical Sciences
  • NIGMS NIH HHS
  • NIH HHS
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Bajikar, S. S., Sztainberg, Y., Trostle, A. J., Tirumala, H. P., Wan, Y. W., Harrop, C. L., Bengtsson, J. D., Carvalho, C. M. B., Pehlivan, D., Suter, B., Neul, J. L., Liu, Z., Jafar-Nejad, P., Rigo, F., & Zoghbi, H. Y. (2024). Modeling antisense oligonucleotide therapy in MECP2 duplication syndrome human iPSC-derived neurons reveals gene expression programs responsive to MeCP2 levels. Human Molecular Genetics, 33(22), 1986-2001. https://doi.org/10.1093/hmg/ddae135

Vancouver

Bajikar SS, Sztainberg Y, Trostle AJ, Tirumala HP, Wan YW, Harrop CL, et al. Modeling antisense oligonucleotide therapy in MECP2 duplication syndrome human iPSC-derived neurons reveals gene expression programs responsive to MeCP2 levels. Human Molecular Genetics. 2024;33(22):1986-2001. doi:10.1093/hmg/ddae135

BibTeX
@article{Bajikar2024,
  author = {Bajikar, Sameer S and Sztainberg, Yehezkel and Trostle, Alexander J and Tirumala, Harini P and Wan, Ying-Wooi and Harrop, Caroline L and Bengtsson, Jesse D and Carvalho, Claudia M B and Pehlivan, Davut and Suter, Bernhard and Neul, Jeffrey L and Liu, Zhandong and Jafar-Nejad, Paymaan and Rigo, Frank and Zoghbi, Huda Y},
  title = {Modeling antisense oligonucleotide therapy in MECP2 duplication syndrome human iPSC-derived neurons reveals gene expression programs responsive to MeCP2 levels},
  journal = {Human Molecular Genetics},
  year = {2024},
  volume = {33},
  number = {22},
  pages = {1986--2001},
  doi = {10.1093/hmg/ddae135}
}
Kostenlos starten →